Skip to main content

Advertisement

Advertisement

World

Johnson & Johnson’s COVID-19 vaccine is 72% effective in the US, 66% in global trial

Johnson & Johnson’s COVID-19 vaccine is 72% effective in the US, 66% in global trial

A vial and sryinge are seen in front of a displayed Johnson & Johnson logo in this illustration taken Jan 11, 2021. (File photo: Reuters/Dado Ruvic)

REUTERS: Johnson & Johnson on Friday (Jan 29) said its single-dose vaccine was 72 per cent effective in preventing COVID-19 in the US. A lower rate of 66 per cent efficacy was observed in a larger global trial conducted across three continents and against multiple strains of the virus. 

In a trial involving nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 was 66 per cent in Latin America and just 57 per cent in South Africa, where a particularly worrying variant of the novel coronavirus is circulating.

READ: New COVID-19 variants: Do the UK and South Africa virus strains pose a danger to Singapore?

Those results compare to the high bar set by two authorised vaccines from Pfizer-BioNTech and Moderna, which were around 95 per cent effective when given in two doses. Those trials, however, were conducted mainly in the US, before the broad spread of new variants now under the spotlight.

READ: Pfizer-BioNTech COVID-19 vaccine only slightly less effective against key South African mutations: Study

Johnson & Johnson’s main study goal was the prevention of moderate to severe COVID-19, and the vaccine was 85 per cent effective in stopping severe disease and preventing hospitalisation across all geographies and against multiple variants 28 days after immunisation.

That level of prevention "will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19," Dr Paul Stoffels, Johnson & Johnson’s chief scientific officer, said in a statement.

The company plans to seek emergency use authorisation from the US Food and Drug Administration (FDA) next week.

Public health officials have been counting on the Johnson & Johnson vaccine to increase much-needed supply and simplify the US’ immunisation campaign.

Unlike the Pfizer-BioNTech and Moderna vaccines, Johnson & Johnson's does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world with weak transportation infrastructure and insufficient cold storage facilities.

READ: Global COVID-19 cases exceed 100 million

SOUTH AFRICA

Several studies have emerged this month showing that a South African variant of the coronavirus has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.

"What we are learning is there is different efficacy in different parts of the world," Stoffels said in a telephone interview.

Importantly, in a sub-study of 6,000 volunteers in South Africa, Stoffels said, the Johnson & Johnson vaccine was 89 per cent effective at preventing severe disease. Ninety-five percent of cases in the South Africa portion of the trial were infections with the South African variant.

A mid-stage trial of a Novavax vaccine in South Africa also showed lower efficacy in the country. It proved to be 60 per cent effective among volunteers who did not have HIV. In a separate, late-stage trial in the UK, the vaccine was 89 per cent effective.

In the Johnson & Johnson trial, which was conducted in eight countries, 44 per cent of participants were from the US, 41 per cent were from Central and South America and 15 per cent were from South Africa. Slightly more than a third of the volunteers were over age 60.

There were no serious adverse events among those who received the shot, the company said. Full results will be published in a peer-reviewed journal.

Johnson & Johnson's vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response.

The Pfizer-BioNTech and Moderna vaccines use a new technology called messenger RNA (mRNA) that requires it to be stored in a freezer.

VACCINE TARGETS

The news of another safe and effective vaccine comes as the US has surpassed 430,000 COVID-19 deaths, with hospitals in many states still struggling to keep up with patients despite recent declines in new infections.

Concerns about fresh surges in the US have also grown due to the presence of a more contagious coronavirus variant first discovered in the UK and news of the arrival of the South African variant on Thursday in South Carolina.

The US vaccination programme got off to a slow start in December and has accelerated to around 1 million shots per day nationwide.

US President Joe Biden has promised that at least 100 million shots will be administered in his first 100 days in office, but concerns about supply disruptions have added uncertainty to that target.

The US has an agreement to buy 100 million doses of Johnson & Johnson's vaccine for US$1 billion. The company said in a statement the vaccine would be ready immediately upon emergency approval, but Stoffels declined to specify how many doses. The government also has the option of purchasing an additional 200 million doses.

Johnson & Johnson has said it plans to deliver 1 billion doses in 2021 and will produce the vaccine in the US, Europe, South Africa and India.

US trial results for the vaccine from AstraZeneca are expected in early February, opening up the possibility of a fourth vaccine option. It has already been approved in the UK, Europe and many countries based on results of a separate trial.

Novavax is also discussing with the FDA whether its data is sufficient to apply for emergency use authorisation.

Johnson & Johnson is studying the effects of its vaccine given in two doses at two months apart, but results of that trial will not be available until this summer, Stoffels said.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/vc

Advertisement

Also worth reading

Advertisement